Bausch + Lomb (NYSE:BLCO) Announces Earnings Results

Bausch + Lomb (NYSE:BLCO) posted its earnings results on Wednesday. The company reported $0.15 EPS for the quarter, missing the consensus estimate of $0.16 by ($0.01), FiscalAI reports. The firm had revenue of $981.15 million during the quarter, compared to the consensus estimate of $1.37 billion. Bausch + Lomb had a positive return on equity of 3.60% and a negative net margin of 4.21%.Bausch + Lomb’s revenue for the quarter was up 9.1% on a year-over-year basis. During the same quarter last year, the company posted ($0.18) EPS.

Here are the key takeaways from Bausch + Lomb’s conference call:

• Strong Q2 execution: Revenue rose 8% on a constant-currency basis to $1.394 billion, while adjusted EBITDA increased 28% to $246 million and margin expanded to 17.6%. Adjusted operating cash flow reached $161 million, supporting a one-turn reduction in leverage since Investor Day to approximately 4.7x.
• Full-year guidance was raised: Revenue guidance increased by $20 million to $5.440-$5.540 billion, and adjusted EBITDA guidance rose by $15 million to $1.025-$1.075 billion. Management now expects approximately 5.8%-7.7% constant-currency revenue growth and an adjusted EBITDA margin of about 19.1% at the midpoint.
• Surgical momentum accelerated: Surgical revenue grew 16% year over year and 17% versus the pre-recall second quarter of 2024, led by 64% growth in implantables and 175% growth in premium IOLs. Premium products represented 13% of surgical revenue in Q2, up from 9% in 2025, improving mix and margins.
• Pharmaceutical growth remained a key driver: Pharma revenue increased 14%, with MIEBO revenue up 44% to $91 million and XIIDRA up 6% to $87 million. Management cited rising MIEBO prescriptions and Medicare coverage increasing to 88% as sources of continued opportunity in dry eye.
• Pipeline activity is advancing, but remains execution-dependent: The company submitted ELIOS, its implant-free MIGS laser, to the FDA and expects second-half readouts for its dual-action dry-eye and ocular-surface-pain candidates. EnVista Beyond remains on track for submission by year-end and potential approval by the end of 2027, subject to ongoing data review and regulatory processes.

Bausch + Lomb Price Performance

NYSE:BLCO traded down $0.07 during trading hours on Wednesday, reaching $16.54. 248,972 shares of the company’s stock were exchanged, compared to its average volume of 431,041. The company has a market capitalization of $5.90 billion, a P/E ratio of -26.67, a price-to-earnings-growth ratio of 0.50 and a beta of 0.56. Bausch + Lomb has a 12 month low of $13.09 and a 12 month high of $18.92. The business’s 50-day simple moving average is $15.90 and its two-hundred day simple moving average is $16.43. The company has a quick ratio of 0.99, a current ratio of 1.53 and a debt-to-equity ratio of 0.78.

Wall Street Analysts Forecast Growth

Several research firms recently commented on BLCO. Citigroup raised their target price on Bausch + Lomb from $19.00 to $21.00 and gave the company a “buy” rating in a research report on Wednesday, July 8th. Weiss Ratings raised Bausch + Lomb from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday. UBS Group began coverage on shares of Bausch + Lomb in a research note on Tuesday. They set a “buy” rating and a $21.00 price objective on the stock. Wall Street Zen raised shares of Bausch + Lomb from a “hold” rating to a “buy” rating in a report on Saturday, April 18th. Finally, Deutsche Bank Aktiengesellschaft set a $16.00 target price on shares of Bausch + Lomb in a research note on Thursday, April 30th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $18.23.

Hedge Funds Weigh In On Bausch + Lomb

Hedge funds and other institutional investors have recently modified their holdings of the stock. Northwestern Mutual Wealth Management Co. lifted its holdings in shares of Bausch + Lomb by 729.3% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 2,322 shares of the company’s stock valued at $30,000 after buying an additional 2,042 shares during the last quarter. Caitong International Asset Management Co. Ltd increased its position in Bausch + Lomb by 104.1% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 2,227 shares of the company’s stock worth $38,000 after buying an additional 1,136 shares during the last quarter. Wells Fargo & Company MN raised its holdings in Bausch + Lomb by 31.2% during the fourth quarter. Wells Fargo & Company MN now owns 5,903 shares of the company’s stock valued at $101,000 after buying an additional 1,403 shares in the last quarter. Focus Partners Wealth bought a new stake in shares of Bausch + Lomb during the 3rd quarter worth about $170,000. Finally, Invesco Ltd. bought a new stake in Bausch + Lomb during the fourth quarter worth approximately $178,000. Institutional investors and hedge funds own 11.07% of the company’s stock.

Key Bausch + Lomb News

Here are the key news stories impacting Bausch + Lomb this week:

• Positive Sentiment: Broad-based growth and raised guidance: Bausch + Lomb reported broad-based second-quarter growth and raised its fiscal 2026 outlook. The company now expects full-year revenue of approximately $5.44 billion to $5.54 billion, compared with a FactSet consensus estimate of $5.47 billion. Bausch + Lomb Delivers Broad-Based Second-Quarter Growth, Raises Full-Year 2026 Guidance
• Positive Sentiment: Earnings improved year over year: Quarterly adjusted earnings were reported at $0.16 per share, matching the Zacks consensus estimate and rising from $0.07 a year earlier. The earnings improvement supports the company’s profitability recovery narrative. Bausch + Lomb Q2 Earnings Meet Estimates
• Positive Sentiment: UBS upgrade: UBS upgraded BLCO to “strong-buy” and assigned a $21 price target, implying substantial upside from the reported trading level. The endorsement may increase investor confidence in the company’s growth and execution prospects. UBS Upgrade Report
• Neutral Sentiment: Mixed earnings-data reports: One report listed EPS at $0.15, slightly below consensus, while another reported $0.16 in line with estimates. Reported revenue figures also appear inconsistent, so investors may focus on the company’s official release and conference call for clarification. Bausch + Lomb Earnings Report and Conference Call

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.